These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33164665)

  • 41. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Candida tropicalis burn wound sepsis: A series of histopathology-confirmed cases.
    Fan C; Tian Q; Huang G; Zhang L; Wu Q; Zhang K
    Intensive Crit Care Nurs; 2018 Jun; 46():6-9. PubMed ID: 29673562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimising antimicrobial therapy through the use of Bayesian dosing programs.
    Avent ML; Rogers BA
    Int J Clin Pharm; 2019 Oct; 41(5):1121-1130. PubMed ID: 31392582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.
    Winterboer TM; Lecci KA; Olsen KM
    J Pharm Pract; 2010 Feb; 23(1):6-18. PubMed ID: 21507788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and Pharmacodynamics of Antimicrobials in Critically Ill Patients.
    Owen EJ; Gibson GA; Buckman SA
    Surg Infect (Larchmt); 2018; 19(2):155-162. PubMed ID: 29272204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.
    Gomez DS; Sanches-Giraud C; Silva CV; Oliveira AM; da Silva JM; Gemperli R; Santos SR
    J Antibiot (Tokyo); 2015 Mar; 68(3):143-7. PubMed ID: 25227503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
    Tsai D; Lipman J; Roberts JA
    Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.
    Blot SI; Pea F; Lipman J
    Adv Drug Deliv Rev; 2014 Nov; 77():3-11. PubMed ID: 25038549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents.
    Estes L
    Mayo Clin Proc; 1998 Nov; 73(11):1114-22. PubMed ID: 9818049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients.
    Carter BL; Damer KM; Walroth TA; Buening NR; Foster DR; Sood R
    J Burn Care Res; 2015; 36(6):641-50. PubMed ID: 25423436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical antimicrobials for burn wound infections.
    Dai T; Huang YY; Sharma SK; Hashmi JT; Kurup DB; Hamblin MR
    Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):124-51. PubMed ID: 20429870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic antimicrobial prophylaxis in burn patients: systematic review.
    Ramos G; Cornistein W; Cerino GT; Nacif G
    J Hosp Infect; 2017 Oct; 97(2):105-114. PubMed ID: 28629932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.
    Phe K; Heil EL; Tam VH
    J Infect Dis; 2020 Jul; 222(Suppl 2):S132-S141. PubMed ID: 32691832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.
    Olbrisch K; Kisch T; Thern J; Kramme E; Rupp J; Graf T; Wicha SG; Mailänder P; Raasch W
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):229-241. PubMed ID: 30368548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Management of severe burns during the 1st 72 hours].
    Gueugniaud PY
    Ann Fr Anesth Reanim; 1997; 16(4):354-69. PubMed ID: 9750581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
    Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
    Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway.
    Surg Infect (Larchmt); 2017; 18(8):846-853. PubMed ID: 29173054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement in survival with peptidyl membrane interactive molecule D4B treatment after burn wound infection.
    Gamelli RL; He LK; Liu H; Ricken JD
    Arch Surg; 1998 Jul; 133(7):715-20. PubMed ID: 9687998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antimicrobial agents in pediatric cancer patients with hepatic or renal impairment].
    Kolve H; Silling G; Ritter J; Groll AH
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S150-64. PubMed ID: 16288361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Special pharmacokinetics of fluconazole in septic, obese and burn patients.
    Pittrow L; Penk A
    Mycoses; 1999; 42 Suppl 2():87-90. PubMed ID: 10865911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.